"Inclisiran First" Strategy; ASCVD; VICTORION-INITIATE; LDL

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Beneficial effects of GLP-1RA in patients with obesity-related HFpEF and T2D
Beneficial effects of GLP-1RA in patients with obesity-related HFpEF and T2D
ACC.24
Beneficial effects of GLP-1RA in patients with obesity-related HFpEF and T2D
- Mikhail Kosiborod, MD
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
ACC.24
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
- James Januzzi, MD
Long-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
Long-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
ACC.24
Long-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
- Alexander Fanaroff, MD
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
ACC.24
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
- Akshay S. Desai, MD

Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD